Protein C

A vitamin-K dependent zymogen present in the blood, which, upon activation by thrombin and thrombomodulin exerts anticoagulant properties by inactivating factors Va and VIIIa at the rate-limiting steps of thrombin formation.

Networked: 5312 relevant articles (168 outcomes, 599 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Griffin, John H: 63 articles (01/2021 - 06/2002)
2.	Esmon, Charles T: 46 articles (01/2022 - 01/2002)
3.	Levi, Marcel: 33 articles (11/2017 - 06/2003)
4.	van der Poll, Tom: 31 articles (01/2022 - 06/2003)
5.	Fernández, José A: 29 articles (01/2021 - 06/2002)
6.	Zlokovic, Berislav V: 26 articles (01/2020 - 05/2003)
7.	Rosing, Jan: 23 articles (01/2017 - 07/2002)
8.	Matthay, Michael A: 21 articles (01/2021 - 04/2003)
9.	Mosnier, Laurent O: 21 articles (12/2020 - 09/2004)
10.	Grinnell, Brian W: 20 articles (01/2015 - 12/2002)

Related Diseases

1.	Sepsis (Septicemia) 10/14/2005 - "The studies, PROWESS and ADDRESS, enrolled a total of 4329 patients with risk ratio (RR) and 95% confidence interval (CI) data for effect on 28-day mortality relative to control treatment of 0.92 (0.83-1.02) suggesting that recombinant human activated protein C is not beneficial in severe sepsis. " 02/01/2003 - "The prospective, randomized, double-blind, placebo-controlled, Phase III, multicenter Recombinant Human Activated Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) trial suggested that drotrecogin alfa--recombinant human activated protein C--significantly improved 28-day mortality rates in acute sepsis (P = 0.005). " 07/31/2014 - "Activated protein C (aPC) plays a pivotal role in modulating a severe inflammatory response and is thought to be beneficial for patients with sepsis. " 05/01/2012 - "Recombinant human activated protein C use was associated with a significant improvement in hospital mortality in patients who participated in the Surviving Sepsis Campaign." 01/01/2005 - "Single compounds such as activated protein C, which acts on multiple pathways, can be expected to be beneficial in rescuing the microcirculation in sepsis."
2.	Septic Shock (Toxic Shock Syndrome) 01/01/2009 - "Recombinant human activated Protein C (APC) is used as an adjunctive therapeutic treatment in septic shock. " 09/01/2014 - "Among patients with septic shock, do-not-resuscitate status acts as a strong confounder that may inform past discrepancies between observational and randomized studies of activated protein C. " 11/01/2012 - "Improvements in general quality of care such as speed of antimicrobial delivery leading to decreasing mortality of patients with septic shock may have contributed to the null results of the recently completed trial of recombinant human activated protein C in patients with septic shock." 11/01/2012 - "To evaluate the effectiveness of recombinant human activated protein C on mortality in a cohort of patients with septic shock and to explore possible reasons for inconsistent results in previous studies. " 11/01/2008 - "Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock."
3.	Inflammation (Inflammations) 06/01/2003 - "The only molecule which has proven to be notably effective in reducing mortality is Activated Protein C interacting on coagulation/fibrinolysis, as well as on inflammation processes. " 12/01/2005 - "These results demonstrated the expression of components of the protein C pathway on gastric epithelial cells and that APC may play a critical role in the protection against gastric mucosal inflammation." 01/01/2015 - "In this study, we hypothesized that pharmacological doses of activated protein C can modulate allergic inflammation by inhibiting dendritic cells. " 01/01/2012 - "Activated Protein C Does Not Alleviate the Course of Systemic Inflammation in the APCAP Trial." 07/01/2009 - "Activated protein C (APC), a crucial mediator in the coagulation process, plays a prominent role in the crosstalk between coagulation and inflammation and provides cytoprotective effects via inhibition of apoptosis and inflammation in several human and animal studies. "
4.	Hemorrhage 07/01/2008 - "In patients with predisposition to bleeding, as in preterm infants, the inactivated form of protein C could serve as a safe therapeutic option. " 03/01/2015 - "Further study of the immunomodulatory effects of protein C may be warranted using mutant forms with decreased bleeding potential. " 01/01/2009 - "These data suggest that strict adherence to PROWESS trial exclusion criteria would further limit serious bleeding events associated with the use of recombinant human activated protein C." 09/01/2008 - "Activated protein C seems to increase the risk of (severe) bleeding, although the absolute risk is low in patients that were included in clinical trials. " 05/01/2004 - "Protein C, given as a plasma concentrate, can exert its therapeutic actions only after activation once in the blood stream: clinical trials with the use of protein C concentrate failed to show any increased risk of bleeding or related disorders. "
5.	Protein C Deficiency 04/01/1994 - "Identification of the spatial relationships of natural mutations in the protein C model is helpful for understanding manifestations of protein C deficiency and for identification of novel, functionally important molecular features and exosites." 04/15/1999 - "In the present study, we screened for protein C amidolytic activity in patients admitted to the National Cardiovascular Center Hospital, and we identified among them 43 probands and 51 relatives with heterozygous protein C deficiency. " 05/01/1994 - "The familial study revealed that her sister and mother had both a decreased concentration and depressed activity of protein C, indicating that this is a case of congenital protein C deficiency. " 12/30/1983 - "Additional studies in the families of the protein C deficient patients revealed further 7 family members with protein C deficiency. " 12/01/2023 - "Mutations in the protein C (PROC) gene can cause protein C deficiency, leading to this disorder. "

Related Drugs and Biologics

1.	drotrecogin alfa activated (Xigris)
2.	Anticoagulants
3.	Protein S
4.	Antithrombin III
5.	Heparin (Liquaemin)
6.	Antithrombins
7.	Dacarbazine (DIC)
8.	Surface-Active Agents (Surfactants)
9.	Proteins (Proteins, Gene)
10.	lipoprotein-associated coagulation inhibitor (TFPI)

Related Therapies and Procedures

1.	Therapeutics
2.	Resuscitation
3.	Catheters
4.	Artificial Respiration (Mechanical Ventilation)
5.	Surgical Amputation (Amputations)